It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The World Health Organization (WHO) has published guidance recommending systemic corticosteroids for the treatment of patients with severe or critical COVID-19 and no corticosteroids for those with nonsevere COVID-19. Although their recommendations for critical cases were based on the results from seven randomized controlled trials (RCTs), those for noncritical cases were based on the results from only one RCT, the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial. In search of additional evidence of corticosteroids’ effect on COVID-19, we systematically reviewed controlled observational studies, besides RCTs, that assessed the impact of corticosteroid treatment on any type of mortality and/or other outcomes in noncritical patients. Of the 4037 titles and abstracts screened, we ultimately included the RECOVERY trial and five controlled observational studies using propensity score matching, (accessed on September 8, 2020). Two of the controlled observational studies assessed the association between corticosteroid treatment and in-hospital mortality, without finding statistical significance. Four of the controlled observational studies assessed corticosteroids’ effect on other outcomes, demonstrating that they were associated with reduced risk of intubation in patients requiring oxygen and with longer hospitalization and viral shedding in mild or moderate cases. These results support the WHO recommendations not to use corticosteroids for nonsevere COVID-19.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Oita University Faculty of Medicine, Department of Respiratory Medicine and Infectious Diseases, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
2 Kanagawa Cardiovascular and Respiratory Center, Department of Respiratory Medicine, Yokohama, Japan (GRID:grid.419708.3) (ISNI:0000 0004 1775 0430)
3 Nagasaki University Graduate School of Biomedical Sciences, Department of Respiratory Medicine, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273)
4 Toho University School of Medicine, Department of Microbiology and Infectious Diseases, Japanese Association for Infectious Disease, Tokyo, Japan (GRID:grid.265050.4) (ISNI:0000 0000 9290 9879)
5 Oita University Faculty of Medicine, Department of Respiratory Medicine and Infectious Diseases, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553); Oita University Faculty of Medicine, Department of Medical Safety Management, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
6 Oita University Faculty of Medicine, Department of Respiratory Medicine and Infectious Diseases, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553); Nagasaki Harbor Medical Center, Nagasaki, Japan (GRID:grid.412334.3)